Adamis Pharmaceuticals Corporation Announces Resignation of Ronald B. Moss as Chief Medical Officer

DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.